[Hybrid-knife endoscopic submucosal dissection]
Mejía J, Pichon Riviere A, Alfie V, Fernandez S, Latorraca M, Alcaraz A, Augustovski F, Garcia Marti S, Bardach A, Ciapponi A
Record ID 32018013155
Spanish
Original Title:
Disección endoscópica de la submucosa con bisturí híbrido
Authors' recommendations:
Low-quality evidence shows that the hybrid knife for endoscopic submucosal dissection in adult patients with premalignant and malignant lesions of the gastrointestinal tract that do not extend beyond the mucosa would not produce a benefit over other types of endoscopic knives, because complete resection, recurrence, bleeding, perforation, and other adverse events were similar with both devices. Its use could reduce surgical time by seven to 26 minutes, although this result comes from low-quality evidence with wide confidence intervals. The clinical practice guidelines from Endoscopy Societies from Europe, North America and Japan do not make recommendations on the use of hybrid knife. Additionally, the Spanish Endoscopy Society clinical practice guideline mentions that it is not possible to draw a conclusion on the superiority of one type of endoscopic knife.
No health funder from European countries, the United States of America or Latin America explicitly mentions coverage of the hybrid knife for endoscopic submucosal dissection in premalignant or malignant lesions in the gastrointestinal tract.
No economic studies conducted in countries of the region assessing its cost-effectiveness or budget impact have been found. However, it has been considered that its cost is high versus endoscopic submucosal dissection using other types of knives. Therefore, its economic dimension is not favorable.
Details
Project Status:
Completed
Year Published:
2024
URL for published report:
https://ets.iecs.org.ar/publication/2191
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Gastrointestinal Neoplasms
- Endoscopic Mucosal Resection
- Endoscopy, Gastrointestinal
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
<p>Institute for Clinical Effectiveness and Health Policy (IECS)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.